Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 1Completed 1

Sponsor Class

OTHER 5INDUSTRY 2NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Carcinoma, Non-Small-Cell Lung 13Neoplasm Metastasis 10Carcinoma, Medullary 10Thyroid Neoplasms 5Lung Neoplasms 5Prostatic Neoplasms 3Neoplasms 3Adenocarcinoma 3Familial medullary thyroid carcinoma 2Colorectal Neoplasms 2Carcinoma, Squamous Cell 2Breast Neoplasms 2Recurrence 1Rectal Neoplasms 1Pleural Effusion 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Multiple Myeloma 1Mesothelioma 1Head and Neck Neoplasms 1Gallbladder Neoplasms 1Differentiated Thyroid Cancer 1Colonic Neoplasms 1Cholangiocarcinoma 1Carcinoma, Large Cell 1Carcinoma, Hepatocellular 1Carcinoma 1Biliary Tract Neoplasms 1Aggression 1Advanced Breast Cancer 1

Interventions

Trastuzumab 209Paclitaxel 187Fulvestrant 161Capecitabine 150Docetaxel 136Letrozole 127exemestane 92palbociclib 76Anastrozole 75Cyclophosphamide 71Lapatinib 69Gemcitabine 66Bevacizumab 66pertuzumab 61ribociclib 60pembrolizumab 60Carboplatin 59abemaciclib 53eribulin 48Doxorubicin 45Vinorelbine 41Everolimus 41Ado-Trastuzumab Emtansine 41Tamoxifen 40130-nm albumin-bound paclitaxel 34Injections 31trastuzumab deruxtecan 30Albumin-Bound Paclitaxel 26olaparib 24Alpelisib 24

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Breast Neoplasms × vandetanib × Clear all
NCT00752986 2016-12-05

ZACFAST

Sanofi

Phase 2 Terminated
39 enrolled 7 charts
Breast

Breast Neoplasms, Neoplasm Metastasis

NCT00034918 2016-08-24

This Study is to Assess the Efficacy and Safety of ZD6474 in Subjects With Metastatic Breast Cancer

Sanofi

Phase 2 Completed
44 enrolled
Breast

Breast Neoplasms, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡